hotspot -WSS

hotspot

author：explore 2025-09-02 13:48:53 - browse：41

Adam's take main illustration — Molly Ferguson/STAT

For two days starting on Sunday, Moonlake Immunotherapeutics happily crunched numbers and shared results from a mid-stage clinical trial that depicted its experimental antibody in the most flattering terms possible.

The drug, called sonelokimab, was “changing the game” for the treatment of a debilitating skin condition called hidradenitis suppurativa, or HS, said Moonlake CEO Jorge Santos da Silva, on a call for investors and analysts. The drug’s benefit for patients placed it “at the top of the heap,” he added.

For other, equally important data from the same study that did not fit Moonlake’s home-run narrative, the company took a DIY approach. Curious about how sonelokimab performed against a treatment that’s already approved for HS? Pull out a calculator and do the math yourself. How badly did a higher dose of the drug underperform a lower dose? Take a guess.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： How one medical school became remarkably diverse
Next article： Does aspartame cause cancer? What new WHO guidance says

WSS

The United States is paying nearly triple for new Covid vaccines

Can CDC director Mandy Cohen drive consensus in Washington?

Medicare innovation center doesn’t save money, experts say

The biotech scorecard for Q4: 16 stock

2023 Nobel Prize in Medicine goes to Karikó and Weissman

IVG is promising — but it won’t replace IVF quite yet

focus

hotspot

explore

In Memoriam: Notable people who died in 2023

Study points to new risk in gene therapy death of Terry Horgan

Activists slam private health insurers over coverage restrictions

Manchin, Huntsman team up to talk platform for 'unity' ticket that could run in 2024

Heart attack and stroke risk calculators need revising

What we owe ALS patients — and why one company fell short

Moonlake's readout produced a cash windfall. Risks remain

Will an HIV vaccine ever be a reality?

Indiana Supreme Court upholds abortion ban, says state constitution gives only limited protections

Blood tests recalled over risk of missed heart attack diagnosis

focus

Congress extends some pandemic preparedness programs

Special counsel informs Trump he is target in probe of efforts to overturn 2020 election

FDA sees ‘potential systemic bias’ in Amgen’s KRAS drug trial

Some top drug companies are starting to take action on climate

Readout Newsletter: Biotech news, Wall Street disappointment, Lilly's drug delays

Congress extends some pandemic preparedness programs

explore

hotspot

focus

entertainment